🔎 Trials Near Me

Beranda › Pendarahan › Illinois

Uji klinis Pendarahan di Illinois

8 studi untuk Pendarahan mencari peserta di lokasi di Illinois.

Kota di Illinois

Teks studi resmi (Bahasa Inggris)

Onyx™ Liquid Embolic IDE Clinical Study

  • University of Chicago, Chicago
Menerima peserta
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06742801

Oxytocin Pharmacokinetics and Pharmacodynamics

  • University of Chicago, Chicago
Menerima pesertaFase 2
Usia 18 hingga 50 · Wanita · Diperbarui 21 Agu 2026 · NCT05488457

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

  • University Of Chicago, Chicago
Menerima pesertaFase 3
1 Month · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06664775

Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

  • Rush University Medical Center, Chicago
Menerima pesertaFase 4Sukarelawan sehat diterima
Usia 18 ke atas · Wanita · Diperbarui 15 Jun 2026 · NCT06820177

Prospective HemorrhoIdaL EmboliSation (PILES) Registry

  • Joint and Vascular Institute, Libertyville
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT07635784

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

  • Children's Hospital of Illinois at OSF Saint Francis Medical Center, Peoria
Menerima pesertaFase 2/3
Hingga usia 17 · Semua jenis kelamin · Diperbarui 8 Jun 2026 · NCT04924322

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

  • University of Chicago, Chicago
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Feb 2026 · NCT06655376

MANAGE-AF Registry -MANAGEment of Atrial Fibrillation Outcomes Registry (MANAGE-AF)

  • CorVita Science Foundation (NFP), Chicago
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Jan 2024 · NCT05978466

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.